Why Is BILLIONTOONE INC A (BLLN) Stock Down Today?

BLLN stock fell 38.59% to $92.10 on Thursday, marking one of the largest declines in the medtech sector. The sharp drop came after the company reported Q2 results that mixed GAAP earnings missing estimates with revenue beating expectations. The stock opened with a 23.3% gap down and continued to trade lower throughout the session, reaching a session low of $91.80. The move coincided with broader weakness in medical research stocks and a wave of insider selling.

What Happened

BillionToOne reported Q2 GAAP EPS of $0.15, which missed estimates by $0.04, while revenue of $109.4 million exceeded expectations by $0.27 million. The mixed results failed to reassure investors, especially in the context of a broader sell-off in the medtech space. The stock opened at $114.97, a significant drop from the previous close of $149.97, and continued to fall throughout the session. By the close, it had lost nearly 39% of its value. The decline was also amplified by a wave of insider selling over the past three weeks, with multiple executives including the CEO and Chief Product Officer offloading shares.

What The Data Shows

The stock has declined 25.2% over the past eight sessions, moving from $133.64 to $100.01. Intraday volume reached 1.5 million shares, more than double the 3-month average. Over the past 90 days, insiders have sold a total of $28.3 million worth of shares, with no insider purchases recorded. The stock is currently trading within its 52-week range of $61.96 to $150.44, and has a market cap of $6.5 billion. Despite the recent drop, the company reaffirmed its FY2026 sales guidance of $450 million to $465 million, slightly above the $456.44 million estimate.

What To Watch

Investors should monitor the company’s upcoming earnings releases and any further insider activity. The stock’s performance may also be influenced by broader market sentiment toward medtech firms and the company’s ability to meet its sales guidance.